Back to Search
Start Over
Apheresis Therapy for Steroid-Resistant Idiopathic Nephrotic Syndrome: Report on a Case Series
- Source :
- Case Reports in Nephrology, Case Reports in Nephrology, Vol 2019 (2019)
- Publication Year :
- 2019
- Publisher :
- Hindawi Limited, 2019.
-
Abstract
- Idiopathic nephrotic syndrome (INS) represents 15%–30% of adulthood glomerulopathies. Corticosteroids have been the main treatment for decades and are effective in 70% of minimal-change disease patients and ~30% of focal segmental glomerulosclerosis patients. Multidrug-resistant (steroids, calcineurin-inhibitors, cyclophosphamide, mycophenolate-mofetil, rituximab) idiopathic nephrotic syndrome is a major therapeutic challenge in nephrology. Apheresis (double-filtration plasmapheresis or semi specific immunoadsorption) could act by eliminating the circulating factor (apolipoproteinA1b, solubleCD40L, suPAR) increasing glomerular permeability seen in INS. The aim of the study was to report the outcome of three patients with multidrug-resistant INS treated successfully with apheresis.
- Subjects :
- Nephrology
medicine.medical_specialty
Cyclophosphamide
business.industry
medicine.medical_treatment
030232 urology & nephrology
Case Report
030204 cardiovascular system & hematology
lcsh:Diseases of the genitourinary system. Urology
lcsh:RC870-923
medicine.disease
Gastroenterology
03 medical and health sciences
0302 clinical medicine
Apheresis
Focal segmental glomerulosclerosis
SuPAR
Internal medicine
medicine
Rituximab
Plasmapheresis
Immunoadsorption
business
medicine.drug
Subjects
Details
- ISSN :
- 2090665X and 20906641
- Volume :
- 2019
- Database :
- OpenAIRE
- Journal :
- Case Reports in Nephrology
- Accession number :
- edsair.doi.dedup.....0ba5a6473f57ad3b958fcf8c0ccb45eb